InfuSystem Holdings Inc

Following INFU’s robust early August momentum breakout, price is tightly consolidating near rising 9- and 20-EMA support with EMAs in bullish alignment. Medium-term bullish structure remains intact while short-term timing is neutral, warranting patience and stalking for a pullback entry into the 9/20 EMA zone.

• ↑Q2 revenue $36.9M, up 2.6% YoY (~7.5% ex restructuring) driven by oncology volume
• ↑Wound care revenue jumped 154% YoY to $2.1M on compression devices
• ↓GE contract restructuring trimmed Q2 revenue by $1.6M, highlighting partnership risk